Fluoroquinolone and rifabutin-containing therapy

Fluoroquinolone-containing therapy and rifabutin-containing therapy are regimens which use proton pump inhibitor and amoxicillin as it is in clarithromycin-containing triple therapy and replaces clarithromycin to levofoxacin, moxifoxacin, or rifabutin, respectively. These regimens are mainly recommended treatments which we can consider as rescue therapies when frst- and second-line eradication therapies fail in Helicobacter pylori treatment. Fluoroquinolone-containing triple therapy is known to show favorable eradication rate and lower adverse events rate compared to bismuth quadruple therapy. However, fuoroquinolone-containing therapy is challenged by steep increase in resistance and subsequent decrease in effcacy. In summary, the antimicrobial resistance to rifabutin is still very low. Nevertheless, it has not been proven whether the eradication effcacy of rifabutin-containing triple therapy is comparable to other alternatives, and still there is a possibility can cause serious side effects, such as bone marrow suppression.